+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Head & Neck Cancer Drugs Market by Drug Class and Sales Channel: Global Opportunity Analysis and Industry Forecast, 2018 - 2025

  • ID: 4828899
  • Report
  • February 2019
  • Region: Global
  • 201 pages
  • Allied Analytics LLP
1 of 4
Head & Neck Cancer Drugs Market Overview:

The global head & neck cancer drugs market was valued at $1,295 million in 2017, and is projected to reach $2,281 million by 2025, registering a CAGR of 7.3% from 2018 to 2025.

Head & neck cancers include a number of different malignant tumors that develop in or around the throat, larynx, nose, sinuses, lips, salivary glands and mouth. Head and neck squamous cell carcinoma (HNSCC) is the most common form of head & neck cancer, which develops in the mucous membranes of the mouth, nose, and throat. Chemotherapy, immunotherapy & targeted therapy are used for the treatment of head & neck cancer along with the radiation & surgical procedures.

There is an increase in the demand for head & neck cancer drugs owing to the growth in incidence of head & neck cancer, rise in demand for combination therapeutics, higher number of R&D studies, and surge in adoption of immune therapeutics. In addition, growth in the geriatric population and technological advancements in screening & diagnosis of head & neck cancer further drive the market growth. Strong presence of late-stage pipeline drugs such as Ipilimumab, Atezolizumab, Avelumab, Durvalumab, Erlotinib, Afatinib, Bevacizumab, and others are expected to drive the market growth. However, higher cost & adverse effect associated with head & neck cancer drugs are projected to impede the market growth.

The global head & neck cancer drugs market is segmented based on drug class, sales channel, and region. Based on drug class, the market is classified as chemotherapy, immunotherapy, and targeted therapy. According to the sales channel, the market is categorized as hospital pharmacies, drug stores and retail pharmacies, and online stores. Based on region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, and rest of LAMEA).

Key Benefits for Head & Neck Cancer Drugs Market:

The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers a quantitative analysis from 2017 to 2025, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
Head & Neck Cancer Drugs Key Market Segments:

By Drug Class

Chemotherapy
Immunotherapy
Targeted Therapy

By Sales Channel

Hospital Pharmacies
Drug Stores & Retail Pharmacies
Online Stores

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA

List of Key Players Profiled in the Report:

AstraZeneca PLC
Bristol-Myers Squibb Company
Eli Lilly and Company (ARMO Biosciences.)
Fortress Biotech, Inc. (Checkpoint Therapeutics, Inc.)
F. Hoffmann-La Roche Ltd. (Genentech, Inc.,)
Immutep Limited
Merck & Co., Inc.
Merck KGaA (EMD Serono, Inc.)
Novartis AG
Pfizer Inc.

List of Other Players in the Value Chain (These players are not profiled in the report. The same will be included on request.)
Boehringer Ingelheim
AVEO Pharmaceuticals
Note: Product cover images may vary from those shown
2 of 4
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.1.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top player positioning
3.3. MARKET DYNAMICS
3.3.1. Drivers
3.3.1.1. Surge in incidence of head and neck cancer worldwide
3.3.1.2. Surge in global geriatric population
3.3.1.3. Increase in consumption of tobacco and alcohol
3.3.2. Restraints
3.3.2.1. Adverse effects associated with the use of head and neck cancer drugs
3.3.3. Opportunities
3.3.3.1. Untapped emerging economies
3.3.3.2. Increase in number of pipeline drugs
3.3.4. Impact Analyses

CHAPTER 4: HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS
4.1. Overview
4.1.1. Market size and forecast
4.2. Chemotherapy
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast
4.2.3. Market analysis, by country
4.3. Immunotherapy
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country
4.4. Targeted therapy
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast
4.4.3. Market analysis, by country

CHAPTER 5: HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL
5.1. Overview
5.1.1. Market size and forecast
5.2. Hospital pharmacy
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Online providers
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Drug stores & retail pharmacies
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country

CHAPTER 6: HEAD & NECK CANCER DRUGS MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends, growth factors, and opportunities
6.2.2. North America market size and forecast, by country
6.2.2.1. U.S.
6.2.2.1.1. U.S. head & neck cancer drugs market, by drug class
6.2.2.1.2. U.S. head & neck cancer drugs market, by sales channel
6.2.2.2. Canada
6.2.2.2.1. Canada head & neck cancer drugs market, by drug class
6.2.2.2.2. Canada head & neck cancer drugs market, by sales channel
6.2.2.3. Mexico
6.2.2.3.1. Mexico head & neck cancer drugs market, by drug class
6.2.2.3.2. Mexico head & neck cancer drugs market, by sales channel
6.2.3. North America market size and forecast, by drug class
6.2.4. North America market size and forecast, by sales channel
6.3. Europe
6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Europe market size and forecast, by country
6.3.2.1. Germany
6.3.2.1.1. Germany head & neck cancer drugs market, by drug class
6.3.2.1.2. Germany head & neck cancer drugs market, by sales channel
6.3.2.2. France
6.3.2.2.1. France head & neck cancer drugs market, by drug class
6.3.2.2.2. France head & neck cancer drugs market, by sales channel
6.3.2.3. UK
6.3.2.3.1. UK head & neck cancer drugs market, by drug class
6.3.2.3.2. UK head & neck cancer drugs market, by sales channel
6.3.2.4. Italy
6.3.2.4.1. Italy head & neck cancer drugs market, by drug class
6.3.2.4.2. Italy head & neck cancer drugs market, by sales channel
6.3.2.5. Spain
6.3.2.5.1. Spain head & neck cancer drugs market, by drug class
6.3.2.5.2. Spain head & neck cancer drugs market, by sales channel
6.3.2.6. Rest of Europe
6.3.2.6.1. Rest of Europe head & neck cancer drugs market, by drug class
6.3.2.6.2. Rest of Europe head & neck cancer drugs market, by sales channel
6.3.3. Europe market size and forecast, by drug class
6.3.4. Europe market size and forecast, by sales channel
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Asia-Pacific market size and forecast, by country
6.4.2.1. Japan
6.4.2.1.1. Japan head & neck cancer drugs market, by drug class
6.4.2.1.2. Japan head & neck cancer drugs market, by sales channel
6.4.2.2. China
6.4.2.2.1. China head & neck cancer drugs market, by drug class
6.4.2.2.2. China head & neck cancer drugs market, by sales channel
6.4.2.3. Australia
6.4.2.3.1. Australia head & neck cancer drugs market, by drug class
6.4.2.3.2. Australia head & neck cancer drugs market, by sales channel
6.4.2.4. India
6.4.2.4.1. India head & neck cancer drugs market, by drug class
6.4.2.4.2. India head & neck cancer drugs market, by sales channel
6.4.2.5. South Korea
6.4.2.5.1. South Korea head & neck cancer drugs market, by drug class
6.4.2.5.2. South Korea head & neck cancer drugs market, by sales channel
6.4.2.6. Rest of Asia-Pacific
6.4.2.6.1. Rest of Asia-Pacific head & neck cancer drugs market, by drug class
6.4.2.6.2. Rest of Asia-Pacific head & neck cancer drugs market, by sales channel
6.4.3. Asia-Pacific market size and forecast, by type
6.4.4. Asia-Pacific market size and forecast, by sales channel
6.5. LAMEA
6.5.1. Key market trends, growth factors, and opportunities
6.5.2. LAMEA market size and forecast, by country
6.5.2.1. Brazil
6.5.2.1.1. Brazil head & neck cancer drugs market, by drug class
6.5.2.1.2. Brazil head & neck cancer drugs market, by sales channel
6.5.2.2. Saudi Arabia
6.5.2.2.1. Saudi Arabia head & neck cancer drugs market, by drug class
6.5.2.2.2. Saudi Arabia head & neck cancer drugs market, by sales channel
6.5.2.3. South Africa
6.5.2.3.1. South Africa head & neck cancer drugs market, by drug class
6.5.2.3.2. South Africa head & neck cancer drugs market, by sales channel
6.5.2.4. Rest of LAMEA
6.5.2.4.1. Rest of LAMEA head & neck cancer drugs market, by drug class
6.5.2.4.2. Rest of LAMEA head & neck cancer drugs market, by sales channel
6.5.3. LAMEA market size and forecast, by type
6.5.4. LAMEA market size and forecast, by sales channel

CHAPTER 7: COMPANY PROFILES
7.1. AstraZeneca Plc.
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product Portfolio
7.1.5. Business performance
7.2. Bristol-Myers Squibb Company
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.2.6. Key strategic moves and developments
7.3. Eli Lilly and Company
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product Portfolio
7.3.5. Business performance
7.4. F. Hoffmann-La Roche Ltd. (Genentech, Inc.,)
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.5. Fresenius Medical Care AG & Co. KGaA
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product Portfolio
7.5.5. Business performance
7.6. Merck & Co., Inc.
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product Portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments
7.7. Pfizer Inc.
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product Portfolio
7.7.5. Business performance
7.8. Sanofi
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product Portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments
7.9. Sun Pharmaceutical Industries Ltd.
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product Portfolio
7.9.5. Business performance
7.10. Teva Pharmaceutical Industries Limited
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product Portfolio
7.10.5. Business performance
7.10.6.Key strategic moves and developments
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
According to this report titled 'Head & Neck Cancer Drugs Market by Drug Class and Sales Channel: Global Opportunity Analysis and Industry Forecast, 2018 - 2025,' the global head & neck cancer drugs market was valued at $1,295 million in 2017, and is expected to reach $2,281 million by 2025, growing at a CAGR of 7.3% from 2018 to 2025.

Head & neck cancer drugs include chemotherapy and targeted & immune therapeutic drugs, which are used alone or in combination for treatment of throat, larynx, nose, sinuses, lips, salivary glands, and mouth cancers. It is estimated that head & neck cancer drugs market is expected to exhibit significant market growth over the forecast period due to growth in number of target population, rise in demand for combination therapy, advancement in screening & diagnosis procedures, and expected launch of pipeline drugs such as Ipilimumab, Atezolizumab, Avelumab, Durvalumab, Erlotinib, Afatinib, and Bevacizumab.

Based on drug class, the global head & neck cancer drugs market is categorized as chemotherapy agents, immunotherapy, and targeted therapy. Chemotherapy was the major revenue contributing segment in 2017, due to increase in adoption of chemotherapeutics for treatment of head & neck cancer along with radiation therapy and rise in demand for combination therapy. However, the market for immune therapeutic drugs is projected to exhibit the fastest market growth during the forecast period owing to strong presence of pipeline drugs, rise in usage of Yervoy & Keytruda along with the supportive reimbursement policies for usage of immunotherapy drugs in some countries.

According to sales channel, the market is classified into hospital pharmacies, drug stores & retail pharmacies, and online stores. Currently, drug stores & retail pharmacies segment is major revenue contributor due to massive presence of these pharmacies. However, online providers segment is expected to show fastest market growth over the forecast period due to rise in preference for online purchasing of drugs over the traditional methods and increase in awareness about online pharmacy with rise in number of internet users.

Key Findings of the Head & Neck Cancer Drugs Market:

Based on sales channel, the online stores segment is expected to experience fastest market and is projected to grow at a CAGR of 10.2% during the forecast period 2018-2025.
Depending on drug class, the chemotherapy segment held nearly half of the global market share in 2017, and is projected to grow at a CAGR of 4.0% from 2018 to 2025.
Region wise, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 9.7% during the forecast period.

North America accounted for nearly one-half of the global market share in 2017, and is expected to remain dominant throughout the forecast period. This was attributed to higher demand for head & neck cancer drugs, higher number target population, favorable reimbursement policies in healthcare system, increase in number of trained medical professionals with wide availability of the advance therapeutics. However, Asia-Pacific is expected to experience the highest growth rate during the forecast period majorly due to growing prevalence of head & neck cancer, upsurge in demand for head & neck cancer drugs with improvement in healthcare infrastructure.
Note: Product cover images may vary from those shown
5 of 4

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Adroll
adroll